[go: up one dir, main page]

GB2478072B - Anti-tumoural effects of cannabinoid combinations - Google Patents

Anti-tumoural effects of cannabinoid combinations

Info

Publication number
GB2478072B
GB2478072B GB1105991.2A GB201105991A GB2478072B GB 2478072 B GB2478072 B GB 2478072B GB 201105991 A GB201105991 A GB 201105991A GB 2478072 B GB2478072 B GB 2478072B
Authority
GB
United Kingdom
Prior art keywords
tumoural
cannabinoid combinations
effects
cannabinoid
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1105991.2A
Other versions
GB2478072A (en
GB201105991D0 (en
Inventor
Guillermo Velasco Diez
Manuel Guzman Pastor
Mar Lorente
Sofia Torres
Fatima Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Original Assignee
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd, Otsuka Pharmaceutical Co Ltd filed Critical GW Pharma Ltd
Priority to GB1105991.2A priority Critical patent/GB2478072B/en
Priority claimed from GB0810195.8A external-priority patent/GB2471987B/en
Publication of GB201105991D0 publication Critical patent/GB201105991D0/en
Publication of GB2478072A publication Critical patent/GB2478072A/en
Application granted granted Critical
Publication of GB2478072B publication Critical patent/GB2478072B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1105991.2A 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations Active GB2478072B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1105991.2A GB2478072B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0810195.8A GB2471987B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations
GB1105991.2A GB2478072B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations

Publications (3)

Publication Number Publication Date
GB201105991D0 GB201105991D0 (en) 2011-05-18
GB2478072A GB2478072A (en) 2011-08-24
GB2478072B true GB2478072B (en) 2012-12-26

Family

ID=44072184

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1105991.2A Active GB2478072B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations

Country Status (1)

Country Link
GB (1) GB2478072B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125859B2 (en) 2010-03-30 2015-09-08 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US9474726B2 (en) 2014-06-17 2016-10-25 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US9522123B2 (en) 2009-07-03 2016-12-20 Gw Pharma Limited Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US10092525B2 (en) 2014-10-14 2018-10-09 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10729665B2 (en) 2011-09-29 2020-08-04 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11065209B2 (en) 2014-10-14 2021-07-20 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US11147776B2 (en) 2014-06-27 2021-10-19 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11357741B2 (en) 2015-06-17 2022-06-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
US11684598B2 (en) 2015-08-10 2023-06-27 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid
US12064398B2 (en) 2016-07-01 2024-08-20 Jazz Pharmaceuticals Research Uk Limited Parenteral formulations
US12161607B2 (en) 2017-02-27 2024-12-10 Jazz Pharmaceuticals Research Uk Limited Combination of cannabinoids in the treatment of leukemia
US12213985B2 (en) 2016-07-01 2025-02-04 Jazz Pharmaceuticals Research Uk Limited Oral cannabinoid formulations
US12263139B2 (en) 2017-06-23 2025-04-01 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of tuberous sclerosis complex
US12357586B2 (en) 2011-01-04 2025-07-15 Jazz Pharmaceuticals Research Uk Limited Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US12383567B2 (en) 2017-12-01 2025-08-12 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058445A1 (en) * 2000-02-11 2001-08-16 Universidad Complutense De Madrid Therapy with cannabinoids in the treatment of cerebral tumor
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
WO2008144475A1 (en) * 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058445A1 (en) * 2000-02-11 2001-08-16 Universidad Complutense De Madrid Therapy with cannabinoids in the treatment of cerebral tumor
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
WO2008144475A1 (en) * 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Medical Hypotheses (2006), Vol. 66, pp234-246 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522123B2 (en) 2009-07-03 2016-12-20 Gw Pharma Limited Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US12023305B2 (en) 2010-03-30 2024-07-02 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US9125859B2 (en) 2010-03-30 2015-09-08 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US10799467B2 (en) 2010-03-30 2020-10-13 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US12357586B2 (en) 2011-01-04 2025-07-15 Jazz Pharmaceuticals Research Uk Limited Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US12121499B2 (en) 2011-09-29 2024-10-22 Gw Pharma Ltd. Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US10729665B2 (en) 2011-09-29 2020-08-04 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11963937B2 (en) 2014-06-17 2024-04-23 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11311498B2 (en) 2014-06-17 2022-04-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US9474726B2 (en) 2014-06-17 2016-10-25 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US11766411B2 (en) 2014-06-17 2023-09-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11701330B2 (en) 2014-06-17 2023-07-18 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11154516B2 (en) 2014-06-17 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11793770B2 (en) 2014-06-27 2023-10-24 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US11147776B2 (en) 2014-06-27 2021-10-19 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US10966939B2 (en) 2014-10-14 2021-04-06 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11633369B2 (en) 2014-10-14 2023-04-25 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12427160B2 (en) 2014-10-14 2025-09-30 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11154517B2 (en) 2014-10-14 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10137095B2 (en) 2014-10-14 2018-11-27 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US11400055B2 (en) 2014-10-14 2022-08-02 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10092525B2 (en) 2014-10-14 2018-10-09 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US12318356B2 (en) 2014-10-14 2025-06-03 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11446258B2 (en) 2014-10-14 2022-09-20 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10111840B2 (en) 2014-10-14 2018-10-30 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10709674B2 (en) 2014-10-14 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11096905B2 (en) 2014-10-14 2021-08-24 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11065209B2 (en) 2014-10-14 2021-07-20 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10709673B2 (en) 2014-10-14 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11357741B2 (en) 2015-06-17 2022-06-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12064399B2 (en) 2015-06-17 2024-08-20 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11684598B2 (en) 2015-08-10 2023-06-27 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12213985B2 (en) 2016-07-01 2025-02-04 Jazz Pharmaceuticals Research Uk Limited Oral cannabinoid formulations
US12064398B2 (en) 2016-07-01 2024-08-20 Jazz Pharmaceuticals Research Uk Limited Parenteral formulations
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
US12161607B2 (en) 2017-02-27 2024-12-10 Jazz Pharmaceuticals Research Uk Limited Combination of cannabinoids in the treatment of leukemia
US12263139B2 (en) 2017-06-23 2025-04-01 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of tuberous sclerosis complex
US12383567B2 (en) 2017-12-01 2025-08-12 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid
US12102619B2 (en) 2020-02-27 2024-10-01 Jazz Pharmaceuticals Research Uk Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11406623B2 (en) 2020-02-27 2022-08-09 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Also Published As

Publication number Publication date
GB2478072A (en) 2011-08-24
GB201105991D0 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
GB2471987B (en) Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) Anti-tumoural effects of cannabinoid combinations
GB2459968B (en) Efficiency-based determination of operational characteristics
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
EP2332387A4 (en) Inter-threading indications of different types of communication
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
PL2133419T3 (en) Uses of cyanophycin beta-dipeptides
IL208281A0 (en) Substituted cyclohexyldiamines
IL209175A0 (en) Substituted qunazolines
EP2247531A4 (en) Reduction of silica
GB0814728D0 (en) New combination
GB0800730D0 (en) Balum splitter
ZA201004979B (en) Extracts of sclerocarya birrea
GB0811100D0 (en) New combination
GB201114396D0 (en) Location of basesation
EP2331490A4 (en) Preparation of dibutoxymethane
GB0806744D0 (en) Novel pyrazole derivatives
EP2297579A4 (en) Determination of distribution
HK1150431A (en) Anti-tumoural effects of cannabinoid combinations
GB0820519D0 (en) Cryropreservation of erythrocytes
PL386302A1 (en) New derivative of isothiazolopyridine
GB0821710D0 (en) Derivatives of dihydroindolone
IL207009A0 (en) Extracts of sclerocarya birrea

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20230323 AND 20230329